{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/mary-ellen-taplin/", "hostname": "dana-farber.org", "description": "Mary-Ellen Taplin, MD - Medical Oncology. Dr. Taplin received her MD in 1986 from the University of Massachusetts, Worcester. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center and an oncology-hematology fellowship at Beth Israel Hospital and Harvard Medical School. Dr. Tap...", "sitename": "dana-farber.org", "date": "2018-06-14", "cleaned_text": "and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 Jun 08. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37290800) Randomized Phase III Study of Enzalutamide Compared With Plus Abiraterone for Metastatic Castration-Resistant biomarker. bioRxiv. 2023 Mar 17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36747644) Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37003085) Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS One. 2023; 18(2):e0281508. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36763576) Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. J Nucl Med. 2023 03; 64(3):349-350. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36702553) Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. View in: in BRCA2-mutated A clinical-grade liquid biomarker 132(21). View Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Institute 2023 02 01; 41(4):871-880. Therapy Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: 2022 10; 208(4):838-845. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36082554) Patterns of structural variation define prostate cancer across disease states. JCI Insight. 2022 09 08; 7(17). Sequencing Improves Detection of Pathogenic Germline Variants in Aug; BRCA1, and PALB2 in 2022 40(26):3011-3014. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference \"What Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer. 2022 06 15; 128(12):2269-2280. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35333400) The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Cancer 2022 Mar 01; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34907080) Genetic testing in prostate cancer management: Considerations informing primary care. CA Cancer J Clin. 2022 07; 72(4):360-371. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35201622) What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. Prostate. 2022 04; 82(5):584-597. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35084050) The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2021 11 02; 113(11):1453-1459. View features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Rep. 2021 09 07; Abiraterone in Men Prostate Cancer. Clin Cancer 11 Resistance Castration-Resistant 2021 12; 13(16). in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34439209) [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34778690) Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Oncol. 2021 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34197212) Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. Eur 2021 09; 80(3):295-303. View Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clin Cancer Res. 2021 07 01; 27(13):3610-3619. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33849963) Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. 07; 206(1):80-87. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33683939) Transcriptional mediators Med. 2021 03; 27(3):426-433. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33664492) Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: 2 Study. of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. J Urol. 2021 06; 205(6):1689-1697. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33502237) View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33497248) Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Cancer Res. 2021 04 01; 27(7):2011-2022. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33208343) Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32943461) Genomic Predictors or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Cancer Res. 2020 10 15; 80(20):4476-4486. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32868381) Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer Prostatic Dis. 2021 03; 24(1):210-219. (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin 09 NRG1 Promotes Antiandrogen in Prostate Cancer Cell. 2020 08 10; 38(2):279-296.e9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32679108) Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811. View in: Gleason pattern 4 stratifies risk of metastasis and death in patients with Gleason score 3+5=8/5+3=8 positive prostate core biopsies. Hum 99:62-74. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32171650) Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. PLoS One. 2020; 15(3):e0229754. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32134978) Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32001144) Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A 10; 27(10):1432-1439. View Survival in Metastatic Castration-resistant Prostate Cancer Treated With [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31542304) Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019 Jul; 51(7):1194. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31152158) Genomic correlates outcome in advanced prostate cancer. Proc Natl Acad Sci U in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31061129) Androgen decline and survival docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2020 03; 23(1):66-73. View Personalized Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. J Res. 2019 05 02; 21(5):e12044. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31045501) Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer. 2019 Prostate Cancer. Res. 2019 Apr 15; 25(8):2672. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30988096) Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2019 12; 22(4):560-568. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30890759) Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. 04 10; 37(11):923-931. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30811282) Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Dis. 2019 09; 22(3):420-427. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30643173) Prostate Cancer-Specific Across Gleason Black Men. JAMA. 2018 12 18; 320(23):2479-2481. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30561471) A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 02 15; 125(4):524-532. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30427533) Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30385733) Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 11 01; 128(11):5185. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30382943) Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018 12 01; 315(6):E1185-E1193. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30325657) Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. Eur Urol. 2019 01; 75(1):44-60. View in: 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res. 2018 11 15; 78(22):6354-6362. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30242112) Rechallenge Prostate Cancer. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30224345) Phosphorylation of androgen is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett. 2018 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30217568) Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30179225) Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018; 2018. View in: Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen Enzalutamide Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 08 15; 78(16):4716-4730. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29921690) Structural Alterations Driving Castration-Resistant Prostate by Sequencing. Cell. 2018 07 12; 174(2):433-447.e19. View A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29882250) Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Soc Clin Oncol Educ Book. 2018 May 23; 38:363-371. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30231388) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018 09; 78(12):889-895. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29707790) Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. J Endocr Soc. 2018 May 01; 2(5):485-496. View in: Study: Effect of Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. J Urol. 2018 08; 200(2):344-352. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29630978) The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29610475) Clinical and Eur Urol. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol. 2018 04; 199(4):990-997. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29331546) Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29331381) Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29263420) Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2018 03; 199(3):683-690. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29203269) Genomic Resistance Patterns Blockade in of Metastatic Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical in: in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29109393) Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018 02; 55(2):307-317.e1. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28941963) Expression of PD-L1 in Hormone-na\u00efve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 23(22):6802-6811. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28842510) The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28762529) Clinical Outcomes of Chemotherapy Na\u00efve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. J Chemotherapy-Na\u00efve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Oncol. 2017 SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4592-4601. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28389510) Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. Elife. 2017 02 cancer: 2017 Jan 01; 123(1):29-42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27802360) Efficacy of Therapies Galeterone 08; II Trial Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27683182) Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 of abiraterone acetate in men with castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2016 12; 19(4):398-405. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27502737) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 04; 375(5):443-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27433846) Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27351382) Redirecting abiraterone 26; 533(7604):547-51. Randomized Phase II of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol. 2016 Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 07 15; 22(14):3672-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26936914) Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26903579) Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26778006) Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clin Cancer Res. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26631610) Androgen Receptor Modulation Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1356-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26527750) Prior Endocrine Therapy Impact Clinical in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Urol. 2016 05; 69(5):924-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26508309) A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from 2015 Nov; in: Jul 16; 162(2):454. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28843286) Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. 161(5):1215-1228. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26000489) Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 2015 Aug 01; 121(15):2603-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25903013) Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network J Nucl Med. 2015 Mar; of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial Ann Oncol. 2015 Apr; 26(4):812-817. View chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25601341) Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report. in Nucl Mol Imaging. supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact. 2015 Jun 05; 234:332-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25514466) Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance 2015 Jun; 13(3):e191-8. View phase I study of everolimus and docetaxel in patients with castration-resistant prostate [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25450031) Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25320358) Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. Oncol. 2014 Nov 20; 32(33):3705-15. in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014 Oct 20; 32(30):3436-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25199761) Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25091040) Enzalutamide in metastatic prostate cancer chemotherapy. N [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24821883) Whole-exome of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24752078) Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24625776) Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24647231) Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr 2014 Apr; 6(4):388-98. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24522233) magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol. 2014 Feb; 7(1):120-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24772215) Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol. 2014 Feb; 10(3):351-62. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24559444) Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. treatment castration-resistant prostate cancer. Hosp Pract (1995). 2013 Oct-Nov; 41(4):81-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24145593) Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. Hematol Oncol Clin North Am. 2013 Dec; 27(6):1261-83, ix. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24188262) Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs. 2013 Sep; 73(13):1417-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23943203) Abiraterone View in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013 Aug 15; 119(16):2990-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23719969) Secondary hormone therapy 2013 May; 27(5):371-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25184257) Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013 Mar; 81(3):611-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23452809) Long-term (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. J Clin Oncol. 20; 31(6_suppl):20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28136936) Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):23. muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28136747) metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23228172) Phase II trial of RAD001 for cancer. BJU Int. 110(11):1729-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22928480) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27; metastases Am J Roentgenol. 2012 Aug; 199(2):367-72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22826398) The evolving paradigm of second-line therapy options castration-resistant prostate androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol. 2012 Feb 10; study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 01; 118(19):4777-84. View in: in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22184381) Secondary therapy in men castration-resistant prostate Clin Genitourin Cancer. 2011 2011 Dec; 9(2):130-2. View of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21632851) SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21606417) II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4642. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28023926) of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4657. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28023914) upper tract: metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr. 2011 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21412093) Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011 Jan; study. Lancet. Apr 24; 375(9724):1437-46. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20398925) Phase II multicenter study of acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Oncol. 2010 Mar in: and dutasteride in View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19887483) Activity of ketoconazole after BJU Activity of dutasteride plus ketoconazole prostate cancer after progression on Genitourin 2009 Oct; 7(3):E90-2. study of castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), with abiraterone acetate plus 2009 May 20; 27(15_suppl):5046. View in: A II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol. 2009 May 20; 27(15_suppl):5060. View MDV3100 of castration-resistant prostate cancer multicenter study acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. 01; 115(5):981-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19152438) Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther. 2008 Sep; 8(9):1495-508. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18759700) Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. 26(15_suppl):5069. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27948759) Impact of prior ketoconazole therapy proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration 2008 May 20; trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer Clin Oncol. 2008 May 20; 26(15_suppl):5068. View in: A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18399827) A Phase II Study of Mifepristone (RU-486) in Castration Resistant Prostate Cancer with Correlative Assessment of Androgen related hormones. BJU. 2008; 101:1084-89. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18293426) Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7. View docetaxel/carboplatin-based chemotherapy and second-line therapy in patients with metastatic hormone-refractory BJU Int. 2008 Feb; 101(3):308-12. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18184327) A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008 Feb 01; 112(3):521-6. View Phase II trial of ketoconazole, hydrocortisone and dutastride (KHAD) for castration resistant prostate cancer (CRPC) with correlative assessment of I trial of RAD001 (R) and docetaxeol (D) in castration resistant prostate cancer (CRPC) with PET assessment of RAD001 prior to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor 26(May of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET endorectal MRI during neoadjuvant hormonal therapy for higher-risk prostate cancer and recurrence in men managed using radiation therapy: Results of CALGB 9682. Int J Radiat trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration Fracture: Evaluation. 2007. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17509304) Phase II study of low dose and high dose premarin in androgen independent prostate cancer. J Urol. 2007; 177(6):2146-50. Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer --2006 Update of an American Society of Clinical Oncology Practice Guideline . J Clin Oncol. 2007; 25(12):1596-605. Initial management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17404365) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 prostate cancer (HRPC) after progression on ketoconzole alone. Proc Am Soc Clin Onc. 2007. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. Proc Am Soc Clin Onc. 2007. Case report and review: a patient with rising PSA after radical prostatectomy treated with docetaxel, estramustine, and 15 months of androgen Am J Hematol Oncol. cancer. and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006 Dec 01; 24(34):5408-13. View in: View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27953925) biochemical Oncol. 2006 Jun 20; 24(18_suppl):4559. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27951992) Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). Jun 20; 24(18_suppl):4560. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27951983) Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing and estramustine Evaluation of prostate-specific antigen declines surrogacy in patients treated on SWOG 99-16. J Cancer Update: Conversations with urologic oncology leaders bridging the gap between research and patient care. 2006. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15; 11(22):8109-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16299243) Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005 Oct; 96(6):783-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16153200) Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005 Aug; 66(2):386-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16098367) Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, in: of as secondary hormonal therapy in androgen-independent prostate cancer (AIPC). (abstract). Proc Am Soc Clin Onc. 2005. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate Am Docetaxel compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1513-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15470214) Quality of life (QOL) and pain in advanced stage prostate cancer: impact of missing data on evaluating palliation in SWOG of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. J Docetaxel carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. J Oncol. 2004 Jul 15; 22(14_suppl):4679. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28015597) Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study serological proteome: the in detection. J Urol. 2004 Jul; 172(1):331-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15201806) American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J 15; 22(14):2927-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15184404) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004 Feb 15; 91(3):483-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14755679) Special Report: evolving role of chemotherapy in the management of prostate cancer. 2004. Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on cancer and leukemia group B (CALGB) 9480. Proc Am Soc Clin Onc. 2004. Quality of life (QOL) and pain in advanced prostate cancer: impact of missing data on evaluating palliation in SWOG 9916. POSTER DISCUSSION. Proc Am Soc Clin Onc. 2004. Chapter 3: External Beam Radiotherapy, Radiopharmaceuticals, and Chemotherapy for Hormone-Refactory Prostate Cancer. In: Management of Skeletal Complications of Prostate Cancer and Other Genitourinary Malignancies. Kantoff PW, Saad F, Smith MR. 2004; 87-151. Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic Am J Hematol. 2003 Dec; 74(4):276-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14635210) The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes. J Clin Oncol. 2003 Oct 01; 21(19):3552-3. mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. 2:S3-S13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16986044) Critical evaluation of hormone therapy for carcinoma of the prostate. Urology. 2002; 60:201-208. Docetaxel (D), estramustine (E) and short-term androgen withdrawal for patients with a rising PSA after definitive local therapy of prostate cancer. Proc Am Soc Clin Onc. 2002. Lack of effect of aminoglutethimide and hydrocortisone added to high-dose bicalutamide for androgen independent prostate cancer. The Prostate J. 2002; 3:1-7. Clinical review 134: The endocrinology for patients with biochemical failure after definitive local therapy for prostate cancer. 2001 Aug; 28(4 studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001 Jul; 159(1):79-92. View low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J May 01; 19(9):2509-16. View in: in androgen prostate cancer (AiPCa) do not correlate with the anti-androgen withdrawal response: Cancer and Leukemia Group (CALGB) 9663. Proc Am Soc Clin Onc. 2001. Androgen receptor advanced prostate cancer: 9663. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. 2000. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group Trial mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999 Jun 01; 59(11):2511-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10363963) A Phase II Study of docetaxel, estramustine and low dose hydrocortisone in hormone Proc Am Soc Clin 1999; 18:295. A Phase II Study of docetaxel, estramustine and low dose hydrocortisone in men with hormone prostate cancer: preliminary results of CALGB 9780. Proc AUA. 1999. Novel therapeutic strategies in prostate cancer. In: D'Amico A, Hanks G, eds. Radiotherapeutic Management of Carcinoma of the Prostate. 1999. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal J Urol. 1998 Jan; 159(1):149-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9400459) Androgen receptor mutations from androgen independent prostate cancer are associated with previous hydroxyflutamide treatment. Keystone Symposium. 1998; 318. GM-CSF Priming with successive concomitant therapy with low-dose ARA-C for older patients with advanced myelodysplastic syndrome (MDS), secondary or refractory acute myeloid leukemia (AML). Am Society of Hematology. 1998. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997 Aug; 3(8):1383-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9815822) Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology. 1996 Mar; 87(3):402-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8778025) Functional analysis of androgen receptor from androgen independent prostate cancer keystone symposia: breast and prostate cancer: Basic Mechanisms. 1996. Bicalutamide prostate cancer. Proc Soc Clin of gene in metastatic androgen-independent prostate cancer. N Engl 1995 May 25; 332(21):1393-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7723794) Androgen receptor mutations in cancer. Proc Am Cancer Res. 1994; 35:273. Androgen receptor mutations in human hormone-independent prostate cancer. J. Cellular Biochemistry. 1994; 239. Repeated intensive cyclophosphamide, doxorubicin and VP-16 with recombinant human granulocyte-macrophage Proc Am Soc Clin Rippe JM, Irwin RS, Alpert JS, Fink M, eds. Intensive Care Medicine. 1991. Presumptive evidence for Blastocystis hominis as a cause of colitis. Arch Intern Med. 1988 May; 148(5):1064. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/3365077) Vitamin B12 "}